SCHEMBL286985

SCHEMBL286985

O=C(NCCOC(=O)c1ccccc1)C1=CN(CC(=O)c2ccc(Cl)cc2Cl)C=CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
TMEM97 Q5BJF2 2/20 0.38
SIGMAR1 Q99720 2/20 0.38
HPGD P15428 2/20 0.38
ALDH1A1 P00352 2/20 0.38
RAB9A P51151 3/20 0.37
KMT2A Q03164 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37
RECQL P46063 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
SLC6A12 P48065 1/20 0.37
ATM Q13315 1/20 0.36
NPC1 O15118 2/20 0.36
MAPT P10636 2/20 0.36
AGTR1 P30556 1/20 0.36
MAPK1 P28482 1/20 0.36
HIF1A Q16665 1/20 0.36
LMNA P02545 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL287234 0.81 ALDH1A1 (0.47) SMN1; SMN2HPGDALDH1A1RAB9ANPC1
SCHEMBL287728 0.80 NPSR1 (0.46) SMN1; SMN2HPGDALDH1A1RAB9AKMT2A
SCHEMBL661570 0.80 ALDH1A1 (0.51) TMEM97SIGMAR1HPGDALDH1A1KMT2A
SCHEMBL660293 0.79 HPGD (0.46) HPGDALDH1A1RAB9AKMT2AL3MBTL1
SCHEMBL287385 0.79 ALDH1A1 (0.46) SMN1; SMN2HPGDALDH1A1RAB9AKMT2A
SCHEMBL660547 0.79 ALDH1A1 (0.39) ALDH1A1KMT2AL3MBTL1POLBNPC1
SCHEMBL662087 0.76 KMT2A (0.47) ALDH1A1KMT2AL3MBTL1POLBTHRB
SCHEMBL286986 0.76 MAPT (0.46) SMN1; SMN2ALDH1A1RAB9AKMT2AL3MBTL1
SCHEMBL7808649 0.75 ALDH1A1 (0.42) HPGDALDH1A1RAB9AKMT2AL3MBTL1
SCHEMBL661158 0.75 TDP1 (0.44) SMN1; SMN2HPGDALDH1A1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP claimed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US claimed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO claimed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS AGER, REN, AGT SMN1; SMN2 640/4885TMEM97 3981/4885SIGMAR1 4746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.